PolyPeptide Group (PPGNE) Stock Overview

Operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. More details

PPGNE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 37.84% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

PPGNE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW429,928 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

429,928 investors already sharing narratives

View all narratives

PolyPeptide Group AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for PolyPeptide Group
Historical stock prices
Current Share Price	CHF 44.00
52 Week High	CHF 0
52 Week Low	CHF 0
Beta	1
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	PPGNE	CH Life Sciences	CH Market
7D	n/a	2.9%	0.2%
1Y	n/a	4.1%	12.2%

Return vs Industry: Insufficient data to determine how PPGNE performed against the Swiss Life Sciences industry.

Return vs Market: Insufficient data to determine how PPGNE performed against the Swiss Market.

Price Volatility

Is PPGNE's price volatile compared to industry and market?
PPGNE volatility
PPGNE Average Weekly Movement	n/a
Life Sciences Industry Average Movement	5.2%
Market Average Movement	3.9%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	2.0%

Stable Share Price: PPGNE's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine PPGNE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1952	1,460	Juan Gonzalez	www.polypeptide.com

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1.

PolyPeptide Group AG Fundamentals Summary

How do PolyPeptide Group's earnings and revenue compare to its market cap?
PPGNE fundamental statistics
Market cap	CHF 1.45b
Earnings (TTM)	CHF 13.64m
Revenue (TTM)	CHF 433.21m

106.5x

P/E Ratio

3.4x

P/S Ratio

Is PPGNE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PPGNE income statement (TTM)
Revenue	€458.86m
Cost of Revenue	€353.95m
Gross Profit	€104.91m
Other Expenses	€90.46m
Earnings	€14.45m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Mar 09, 2027

Earnings per share (EPS)	0.44
Gross Margin	22.86%
Net Profit Margin	3.15%
Debt/Equity Ratio	36.9%

How did PPGNE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/20 22:51
End of Day Share Price	2026/09/18 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PolyPeptide Group AG is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
"Charles Pitman-King	Barclays
Charles Pitman	Barclays
Estelle Bétrisey	Berenberg